272 related articles for article (PubMed ID: 28727166)
1. Hepatocytes contribute to residual glucose production in a mouse model for glycogen storage disease type Ia.
Hijmans BS; Boss A; van Dijk TH; Soty M; Wolters H; Mutel E; Groen AK; Derks TGJ; Mithieux G; Heerschap A; Reijngoud DJ; Rajas F; Oosterveer MH
Hepatology; 2017 Dec; 66(6):2042-2054. PubMed ID: 28727166
[TBL] [Abstract][Full Text] [Related]
2. Impaired Very-Low-Density Lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia.
Hoogerland JA; Peeks F; Hijmans BS; Wolters JC; Kooijman S; Bos T; Bleeker A; van Dijk TH; Wolters H; Gerding A; van Eunen K; Havinga R; Pronk ACM; Rensen PCN; Mithieux G; Rajas F; Kuipers F; Reijngoud DJ; Derks TGJ; Oosterveer MH
J Inherit Metab Dis; 2021 Jul; 44(4):879-892. PubMed ID: 33739445
[TBL] [Abstract][Full Text] [Related]
3. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.
Lei Y; Hoogerland JA; Bloks VW; Bos T; Bleeker A; Wolters H; Wolters JC; Hijmans BS; van Dijk TH; Thomas R; van Weeghel M; Mithieux G; Houtkooper RH; de Bruin A; Rajas F; Kuipers F; Oosterveer MH
Hepatology; 2020 Nov; 72(5):1638-1653. PubMed ID: 32083759
[TBL] [Abstract][Full Text] [Related]
4. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
[TBL] [Abstract][Full Text] [Related]
5. A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia.
Zhou J; Waskowicz LR; Lim A; Liao XH; Lian B; Masamune H; Refetoff S; Tran B; Koeberl DD; Yen PM
Thyroid; 2019 Aug; 29(8):1158-1167. PubMed ID: 31337282
[No Abstract] [Full Text] [Related]
6. Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia.
Gjorgjieva M; Calderaro J; Monteillet L; Silva M; Raffin M; Brevet M; Romestaing C; Roussel D; Zucman-Rossi J; Mithieux G; Rajas F
J Hepatol; 2018 Nov; 69(5):1074-1087. PubMed ID: 30193922
[TBL] [Abstract][Full Text] [Related]
7. Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing.
Arnaoutova I; Zhang L; Chen HD; Mansfield BC; Chou JY
Mol Ther; 2021 Apr; 29(4):1602-1610. PubMed ID: 33359667
[TBL] [Abstract][Full Text] [Related]
8. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.
Kim GY; Lee YM; Kwon JH; Cho JH; Pan CJ; Starost MF; Mansfield BC; Chou JY
Mol Genet Metab; 2017 Mar; 120(3):229-234. PubMed ID: 28096054
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.
Cho JH; Lee YM; Starost MF; Mansfield BC; Chou JY
J Inherit Metab Dis; 2019 May; 42(3):459-469. PubMed ID: 30637773
[TBL] [Abstract][Full Text] [Related]
10. Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia.
Waskowicz LR; Zhou J; Landau DJ; Brooks ED; Lim A; Yavarow ZA; Kudo T; Zhang H; Wu Y; Grant S; Young SP; Huat BB; Yen PM; Koeberl DD
Hum Mol Genet; 2019 Jan; 28(1):143-154. PubMed ID: 30256948
[TBL] [Abstract][Full Text] [Related]
11. Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiency.
Farah BL; Landau DJ; Sinha RA; Brooks ED; Wu Y; Fung SYS; Tanaka T; Hirayama M; Bay BH; Koeberl DD; Yen PM
J Hepatol; 2016 Feb; 64(2):370-379. PubMed ID: 26462884
[TBL] [Abstract][Full Text] [Related]
12. Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia.
Yavarow ZA; Kang HR; Waskowicz LR; Bay BH; Young SP; Yen PM; Koeberl DD
Hum Mol Genet; 2020 Jan; 29(2):286-294. PubMed ID: 31816064
[TBL] [Abstract][Full Text] [Related]
13. Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context.
Monteillet L; Gjorgjieva M; Silva M; Verzieux V; Imikirene L; Duchampt A; Guillou H; Mithieux G; Rajas F
Mol Metab; 2018 Oct; 16():100-115. PubMed ID: 30100243
[TBL] [Abstract][Full Text] [Related]
14. The role of kidney in the inter-organ coordination of endogenous glucose production during fasting.
Kaneko K; Soty M; Zitoun C; Duchampt A; Silva M; Philippe E; Gautier-Stein A; Rajas F; Mithieux G
Mol Metab; 2018 Oct; 16():203-212. PubMed ID: 29960865
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia.
Zhang L; Lee C; Arnaoutova I; Anduaga J; Starost MF; Mansfield BC; Chou JY
Biochem Biophys Res Commun; 2020 Jun; 527(3):824-830. PubMed ID: 32430177
[TBL] [Abstract][Full Text] [Related]
16. An evolutionary approach to optimizing glucose-6-phosphatase-α enzymatic activity for gene therapy of glycogen storage disease type Ia.
Zhang L; Cho JH; Arnaoutova I; Mansfield BC; Chou JY
J Inherit Metab Dis; 2019 May; 42(3):470-479. PubMed ID: 30714174
[TBL] [Abstract][Full Text] [Related]
17. Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels.
Saeed A; Hoogerland JA; Wessel H; Heegsma J; Derks TGJ; van der Veer E; Mithieux G; Rajas F; Oosterveer MH; Faber KN
Hum Mol Genet; 2020 Jan; 29(2):264-273. PubMed ID: 31813960
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte-specific glucose-6-phosphatase deficiency disturbs platelet aggregation and decreases blood monocytes upon fasting-induced hypoglycemia.
La Rose AM; Bazioti V; Hoogerland JA; Svendsen AF; Groenen AG; van Faassen M; Rutten MGS; Kloosterhuis NJ; Dethmers-Ausema B; Nijland JH; Mithieux G; Rajas F; Kuipers F; Lukens MV; Soehnlein O; Oosterveer MH; Westerterp M
Mol Metab; 2021 Nov; 53():101265. PubMed ID: 34091064
[TBL] [Abstract][Full Text] [Related]
19. Hepatic ChREBP orchestrates intrahepatic carbohydrate metabolism to limit hepatic glucose 6-phosphate and glycogen accumulation in a mouse model for acute Glycogen Storage Disease type Ib.
Krishnamurthy KA; Rutten MGS; Hoogerland JA; van Dijk TH; Bos T; Koehorst M; de Vries MP; Kloosterhuis NJ; Havinga H; Schomakers BV; van Weeghel M; Wolters JC; Bakker BM; Oosterveer MH
Mol Metab; 2024 Jan; 79():101838. PubMed ID: 37995884
[TBL] [Abstract][Full Text] [Related]
20. Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR-associated protein 9-Mediated Gene Editing.
Rutten MGS; Derks TGJ; Huijkman NCA; Bos T; Kloosterhuis NJ; van de Kolk KCWA; Wolters JC; Koster MH; Bongiovanni L; Thomas RE; de Bruin A; van de Sluis B; Oosterveer MH
Hepatology; 2021 Nov; 74(5):2491-2507. PubMed ID: 34157136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
